Name : Human CLEC4M/CD299 Protein
Product Source :
Recombinant Human CLEC4M/CD299 Protein is expressed from HEK293 without tag. It contains Gln71-Glu399.[Accession | Q9H2X3-1]
Molecular Weight :
The protein has a predicted MW of 37.72 kDa. Due to glycosylation, the protein migrates to 38-50 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human CLEC4M on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human CLEC4M is greater than 95% as determined by SEC-HPLC.
Background :
CLEC4M, also known as DC-SIGNR, L-SIGN or CD209L, is a Ca2+-dependent C-type lectin. CLEC4M and its homologue DC-SIGN are encoded by the closely related lectin gene cluster on chromosome 19p13.3. higher expression of CLEC4M is associated with poor clinical prognosis in lung cancer patients and enhances the resistance of NSCLC cells to cisplatin. Inhibition of CLEC4M expression significantly increased cisplatin sensitivity, suggesting potential clinical significance for targeting CLEC4M in overcoming cisplatin resistance.
Synonyms :
CLEC4M; CD299; DC-SIGNR; DC-SIGN2; L-SIGN; CD209L; CD209L1
References & Citations :
Tan LM, Li X, Qiu CF, Zhu T, Hu CP, Yin JY, Zhang W, Zhou HH, Liu ZQ. CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients. J Cancer. 2019 Oct 19;10(25):6374-6383. doi: 10.7150/jca.30139. PMID: 31772670; PMCID: PMC6856750.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
CRISPR-Cas9 ProteinMolecular Weight
PD-L1 Proteincustom synthesis
Popular categories:
Integrin alpha-3
CCR3